Pharma & Life Sciences SMB (51-200 employees)

Medical Science Liaison at SMB

High Openness and scientific rigor to communicate complex evidence, develop KOLs within regulatory boundaries, and support clinical research.

In SMB pharma, quality and compliance are the license to operate

The development pipeline is the company's valuation and main asset

The relationship with local health authorities is capital built over years

Generic profile Startup (1-50 employees) Enterprise (201-1000 employees) Global (1001+ employees)

Ideal OCEAN+ Profile

Ideal range

Openness

80 95

At SMBs (51-200 employees), scientific depth to interpret clinical studies, discuss mechanisms of action, and stay current with cutting-edge medical literature

Conscientiousness

70 85

At SMBs (51-200 employees), precision in communicating clinical data, adherence to regulatory guidelines, and documentation of medical interactions

Extraversion

68 83

At SMBs (51-200 employees), ability to present complex scientific data to specialist physicians and participate in medical congresses with credibility

Agreeableness

65 80

At SMBs (51-200 employees), building trust-based relationships with KOLs grounded in scientific objectivity and respect for the physician's clinical autonomy

Emotional Stability

65 81

At SMBs (51-200 employees), handling scientific pushback, tough questions from KOLs, and pressure to share off-label data

Structure & Rhythm

65 81

At SMBs (51-200 employees), the MSL combines a structured cadence of visits and follow-up with scientific flexibility; the role requires adherence to approved medical engagement plans and compliance guidelines for KOL interactions

Strengths and Red Flags

Strengths

Communicating complex scientific evidence with rigor and credibility to specialists
Developing and maintaining relationships with high-impact KOLs in the therapeutic area
Managing development pipelines balancing innovation with commercial viability
GMP and regulatory compliance with limited internal quality teams

Red Flags

Promotional behavior that compromises the MSL's scientific credibility
Scientific superficiality that KOLs detect in the first meetings
Difficulty maintaining compliance with limited quality resources
Resists outsourcing activities it can't perform internally

Interview Questions

How do you prepare for a meeting with a KOL who just published a study that contradicts your product's data? What message do you bring, and how do you handle it if the exchange becomes scientifically confrontational?

Evaluates: Scientific Openness and Emotional Stability under expert challenge

A physician asks you about an off-label use of your product for which there is positive preliminary evidence. What exactly do you do in that moment?

Evaluates: Conscientiousness and compliance in medical communication

How did you maintain GMP compliance with limited quality teams?

Evaluates: Conscientiousness and efficiency in quality management

How did you balance innovation with commercial viability in your pipeline?

Evaluates: Balance between scientific rigor and business pragmatism